NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Assembly Biosciences, Inc. ASMB
19 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 72.3M
Revenue, FY2025 · full 19-year series below
Revenue $M
Net income $M
FY2025 · Revenue 72.3 · Net income -6.1
Compound annual growth
Revenue compounded at −1.8% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−8 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -16.8% · Net -8.5%
ROE
FY2025 · ROE -5.1%
Each USD of equity lost 5 cents this year.
The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · |
| Operating income $B | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| EBITDA $B | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | −0.0 | 0.0 | −0.0 | −0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.1 | 0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| EPS, diluted $ | −0.55 | −6.69 | −13.38 | −23.08 | −3.00 | −1.75 | −3.72 | −3.98 | −2.41 | −2.57 | −1.81 | −3.40 | −5.00 | −1.94 | −3.57 | −24.67 | −10.02 | · | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −5.1 | −107.9 | −98.9 | −74.0 | −63.4 | −24.2 | −40.4 | −56.1 | −44.4 | −44.6 | −32.1 | −57.3 | −91.7 | −94.7 | −148.8 | · | · | · | · |
| Shares out B | 0.02 | 0.01 | 0.01 | 0.00 | 0.05 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 67 reconciliationsAUDITED
Reconciled in 19 of 19 fiscal years. 9 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007